B-type natriuretic peptide is a biomarker for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia

Alain Cuna1
Jegen Kandasamy1
Naomi Fineberg2
Brian Sims1

1Department of Pediatrics, Division of Neonatology, 2Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA

Background: B-type natriuretic peptide (BNP) is a cardiac biomarker useful in screening for pulmonary hypertension (PH) in adults. It is possible that BNP may also be useful in detecting PH among preterm infants with bronchopulmonary dysplasia (BPD).

Objective: To determine the utility of BNP for identification of PH among preterm infants with BPD.

Methods: We retrospectively identified preterm infants with BPD who underwent screening echocardiography for suspected PH and had serum BNP levels measured within 10 days before or after echocardiography. Eligible infants were classified based on echocardiographic diagnosis of either PH or no PH. Median and interquartile ranges (IQR) of BNP values were compared, and area under the curve (AUC) of receiver operator characteristic (ROC) analysis was used to determine the optimum threshold value for detection of PH.

Results: Twenty-five preterm infants with BPD (mean gestational age 26.5 ± 1.7 weeks, mean birth weight 747 ± 248 g) were identified. The median difference in days between echocardiography and BNP measurement was 1 day (IQR 0–3, range 0–10 days). Based on echocardiography, 16 were diagnosed with PH and nine without PH. No significant difference in terms of gestational age, birth weight, sex, race, or respiratory support was found between the two groups. Median (IQR) BNP values of those with PH were higher than those without PH (413 [212–1178] pg/mL versus 55 [21–84] pg/mL, P < 0.001). AUC of ROC analysis showed that a BNP value of 117 pg/mL had 93.8% sensitivity and 100% specificity for detecting PH.

Conclusion: BNP estimation may be useful for screening of PH in infants with BPD.

Keywords: B-type natriuretic peptide, pulmonary hypertension, bronchopulmonary dysplasia, biological markers, prematurity

Introduction

Pulmonary hypertension (PH) is one of the most serious complications of bronchopulmonary dysplasia (BPD).1,2 Early detection of PH is important due to its association with significantly worse outcomes.3 However, diagnosis of PH among BPD infants is often delayed due to its subtle symptoms that overlap with respiratory symptoms of BPD itself. Though cardiac catheterization remains the gold standard for diagnosis, it is highly invasive and rarely done as the initial test. Echocardiography has thus become the preferred screening test of choice for PH. However, echocardiography is not always readily available at all institutions and has important limitations of its own.4 Measurement of B-type natriuretic peptide (BNP) has been found effective for the evaluation of patients with suspected PH in adults,5,6 and has been suggested to also be useful in screening infants with BPD for PH.7 There is very limited evidence
however to support this. Thus, this current study aims to investigate the potential utility of BNP in screening for PH in preterm infants with BPD.

**Methods**

The following describes a retrospective study conducted at the Neonatal Intensive Care Units of University of Alabama at Birmingham and Children’s of Alabama, Birmingham, AL, USA. Approval by the local ethics committee was obtained prior to the start of this study.

Extremely preterm infants admitted between September 2010 and August 2012 with BPD were identified from the neonatal database. BPD was diagnosed and graded at 36 weeks postmenstrual age using the physiologic definition for oxygen requirement. The infants’ clinical charts were examined to identify those who: (1) underwent echocardiography as screening for suspected PH and (2) had serum BNP level measured within 10 days before or after echocardiography. Infants with structural heart defects other than a patent ductus arteriosus (PDA) or a patent foramen ovale, and those with multiple congenital anomalies were excluded.

Eligible infants were categorized according to PH based on screening echocardiography results. Echocardiograms were performed by certified technicians and read by board certified pediatric cardiologists. All echocardiograms were performed using Sonos 500 ultrasound machine (Philips Healthcare, Andover, MA, USA). Infants were diagnosed with PH if at least one of the following echocardiographic findings was present: (1) elevated tricuspid regurgitation jet velocity, (2) interventricular septum flattening, (3) right ventricular hypertrophy, or (4) right to left shunting. Data on corresponding serum BNP levels obtained within 10 days of echocardiography were collected. Baseline demographic data and respiratory support at the time of echocardiography were also recorded.

Data were expressed as a median and interquartile range (IQR), mean and standard deviation, or counts and percentage. Association between PH diagnosis and categorical values (sex, race, respiratory support, PDA, BPD) was assessed using Fisher’s exact test. For continuous variables (gestational age, birth weight, age at screening, BNP), t-test or Mann–Whitney U test was used. Area under the receiver-operating characteristic (ROC) curve was computed and optimal cutoff value of BNP for PH diagnosis was established. Log transformation of BNP values to normalize data was also done, and univariate analysis of covariance performed to determine relationship of BNP with PH after controlling for other covariates. A two-sided $P < 0.05$ was considered statistically significant.

**Results**

Twenty-five preterm infants with BPD were identified to have undergone screening echocardiography for PH and also had serum BNP level obtained within 10 days. Mean gestational age was $26.5 \pm 1.7$ weeks and mean birth weight was $747 \pm 248$ g. The median number of days between echocardiography and serum BNP measurement was 1 day (IQR 0 to 3 days, range 0 to 10 days). Sixteen of the infants had PH and nine had no PH on echocardiography. Characteristics of the study participants are shown in Table 1.

Patients with PH were noted to be older at time of screening ($104 \pm 34$ days versus $77 \pm 59$ days, $P = 0.03$) and have higher median BNP values [413 [212–1178] pg/mL versus 55 [21–84] pg/mL, $P < 0.001$]. The other demographics and general findings were otherwise similar between the two groups. After controlling for baseline variables, BNP maintained independent predictive ability for PH ($P < 0.001$). Area under the ROC curve for BNP to diagnose PH was 0.993, with an identified optimal cutoff value of 117 pg/mL. Using this cutoff, BNP showed a sensitivity of 93.8% and a specificity of 100% for diagnosing PH.

**Discussion**

This study broadens the possible application of BNP in neonates to include screening of preterm infants with BPD for PH. Specifically, our results show that an elevated BNP level of >117 pg/mL obtained around the time of screening echocardiography correlated with echocardiographic detection of PH among preterm BPD infants. Our results are consistent with other investigators who have also shown similar utility of BNP as a diagnostic biomarker in neonates with congenital heart disease, hemodynamically significant PDA, and persistent PH of the newborn. Given the limitations of both cardiac catheterization and echocardiography especially in preterm infants, BNP could be an attractive adjunct for screening of PH that is noninvasive, cost-effective, and readily available.

In this study, we did not exclude infants with PDA from analysis. It is possible that the presence of PDA in some of the study infants ($n = 6$) may have contributed to higher BNP levels. However, analysis of covariance confirmed that BNP maintained its strong relationship with PH despite controlling for other variables including PDA. It is also important to note the lack of data on renal function at the time of BNP measurement, as renal dysfunction can also contribute to higher BNP levels. However, no infant in the study had clinical suspicion of renal dysfunction (poor urine output, unstable electrolytes, rising creatinine) at the time of BNP measurement.
A more subtle limitation is the use of echocardiography in determining PH. Though echocardiography is commonly performed as the initial test for detecting PH, it remains a screening test with important limitations. Ideally, a diagnostic biomarker under consideration would be compared with the gold standard, which in the case of PH is cardiac catheterization. However, cardiac catheterization is highly invasive and rarely done especially in premature infants with significant lung disease.

It is interesting to note that BPD infants with PH were older than those without PH. Whether older postnatal age contributed to higher BNP levels among preterm BPD infants with PH is unknown. However studies in both term and preterm infants consistently showed that BNP levels are highest during the first few days of life and decrease with increasing age. A more plausible reason is that majority of PH among preterm BPD infants is diagnosed at a later age. This is consistent with a recent prospective study where screening echocardiography of extremely low birth weight neonates.

Specifically, to determine whether BNP values decrease with treatment and resolution of PH and increase with worsening PH (extremely premature, extremely low birth weight, with significant respiratory support) were screened with echocardiography for PH were included in the study due to lack of corresponding BNP level drawn.

Major limitations of our study remain the small number of patients included and its retrospective nature. A prospective study involving a larger sample size is needed to further determine the usefulness of BNP as a screening tool for PH in preterm infants. Other questions that need to be answered include whether BNP can also be used to follow the course of PH. Specifically, to determine whether BNP values decrease with treatment and resolution of PH and increase with worsening of PH. Also, it would be important to know whether high BNP values correlate with worse clinical status and other important clinical outcomes including length of stay and mortality.

**Disclosure**
The authors report no conflicts of interest in this work.

**References**

---

**Table 1** Baseline characteristics of all BPD infants and comparison between those with and without PH

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All BPD</th>
<th>BPD with PH</th>
<th>BPD without PH</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td>25</td>
<td>16</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Gestational age, weeks</td>
<td>26.45 ± 1.7</td>
<td>26.48 ± 1.9</td>
<td>26.38 ± 1.2</td>
<td>0.89</td>
</tr>
<tr>
<td>Birth weight, g</td>
<td>747.16 ± 248</td>
<td>731.19 ± 298</td>
<td>775.56 ± 130.74</td>
<td>0.14</td>
</tr>
<tr>
<td>Male/female</td>
<td>17/8</td>
<td>12/4</td>
<td>5/4</td>
<td>0.39</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td>1.0</td>
</tr>
<tr>
<td>AA</td>
<td>11 (44%)</td>
<td>7 (43.8%)</td>
<td>4 (44.4%)</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>14 (56%)</td>
<td>9 (56.2%)</td>
<td>5 (55.6%)</td>
<td></td>
</tr>
<tr>
<td>Age at screening, days</td>
<td>94 ± 45</td>
<td>104 ± 34</td>
<td>77 ± 59</td>
<td>0.03</td>
</tr>
<tr>
<td>Respiratory support</td>
<td></td>
<td></td>
<td></td>
<td>0.93</td>
</tr>
<tr>
<td>NC</td>
<td>7 (28%)</td>
<td>4 (25%)</td>
<td>3 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>CPAP</td>
<td>5 (20%)</td>
<td>4 (25%)</td>
<td>1 (11.1%)</td>
<td></td>
</tr>
<tr>
<td>Ventilator</td>
<td>13 (52%)</td>
<td>8 (50%)</td>
<td>5 (55.6%)</td>
<td></td>
</tr>
<tr>
<td>BPD</td>
<td></td>
<td></td>
<td></td>
<td>0.817</td>
</tr>
<tr>
<td>Mild</td>
<td>2 (8%)</td>
<td>1 (6%)</td>
<td>1 (11%)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>2 (8%)</td>
<td>1 (6%)</td>
<td>1 (11%)</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>21 (84%)</td>
<td>14 (88%)</td>
<td>7 (78%)</td>
<td></td>
</tr>
<tr>
<td>PDA</td>
<td>6 (24%)</td>
<td>2 (12.5%)</td>
<td>4 (44.4%)</td>
<td>0.142</td>
</tr>
<tr>
<td>BNP, pg/mL</td>
<td>211 (74, 854)</td>
<td>413 (212, 1178)</td>
<td>55 (21, 84)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Note:** Data are expressed as mean ± SD, as number (percentage), or as median (IQR).

**Abbreviations:** AA, African American; BNP, B-type natriuretic peptide; BPD, bronchopulmonary dysplasia; C, Caucasian; CPAP, continuous positive airway pressure; IQR, interquartile range; NC, nasal cannula; PDA, patent ductus arteriosus; PH, pulmonary hypertension; SD, standard deviation.


